Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 10/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.50 |
| ▸ | USP2 | O75604 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24036994 | 0.86 | PIK3CG (0.52) | PIK3CGCYP1A2CYP3A4TSHRCLK4 | |
| SCHEMBL12578179 | 0.82 | PIK3CG (0.55) | PIK3CGCYP1A2CYP3A4TSHRCLK4 | |
| Ammonia Solution, Strong SCHEMBL4352351 | 0.81 | PIK3CG (0.66) | PIK3CGCYP1A2CYP3A4TSHRCLK4 | |
| SCHEMBL10783440 | 0.76 | SMN1; SMN2 (0.49) | PIK3CGCYP1A2CYP3A4TSHRCLK4 | |
| SCHEMBL30124132 | 0.76 | EGFR (0.54) | PIK3CGCYP1A2CYP3A4TSHRCLK4 | |
| SCHEMBL35632 | 0.76 | EGFR (0.54) | PIK3CGCYP1A2CYP3A4TSHRCLK4 | |
| SCHEMBL3292267 | 0.75 | PIK3CG (0.47) | PIK3CGCYP1A2CYP3A4TSHRCLK4 | |
| SCHEMBL29516689 | 0.73 | MAPK14 (0.63) | ALDH1A1MAPK1LMNAKMT2AL3MBTL1 | |
| SCHEMBL284971 | 0.73 | MAPK14 (0.63) | ALDH1A1MAPK1LMNAKMT2AL3MBTL1 | |
| SCHEMBL6236262 | 0.73 | CYP1A2 (0.56) | PIK3CGCYP1A2CYP3A4TSHRCLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-7691858-B2 | Kinase inhibitors and methods of use thereof | TARGEGEN, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20070259876-A1 | Kinase inhibitors and methods of use thereof | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20050282814-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. (US) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259876-A1 | Kinase inhibitors and methods of use thereof | ROCK1, ADCK1, MAP3K20 | PIK3CG 180/4885CYP1A2 4859/4885CYP3A4 4820/4885 |
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | RBP1, RBP4, VCAM1 | PIK3CG 2378/4885CYP1A2 4876/4885CYP3A4 4829/4885 |
| US-20050282814-A1 | Vasculostatic agents and methods of use thereof | RBP1, RBP4, VCAM1 | PIK3CG 2378/4885CYP1A2 4876/4885CYP3A4 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.